Sweden – Market and economic research; polling and statistics – Datainsamling för Jordbrukets ekonomi och hållbarhet (FSDN)

Sweden – Architectural, construction, engineering and inspection services – Ledningsstöd program Gävle-Kringlan

Sweden – Accounting and auditing services – Revisionstjänster

Under the Paul Coverdell Forensic Science Improvements Grant Program, state administering agencies (SAAs) may be eligible and apply for both formula and competitive funds. This NOFO is ONLY for formula funds. An applicant seeking to apply for Coverdell competitive funds (consistent with 34 U.S.C. § 10563(a)(2)) that are available to eligible states and units of local government would need to apply separately under BJA’s FY 2026 Paul Coverdell Forensic Science Improvement—Competitive Grants Program NOFO.

France – Energy and related services – Marché Public Global de Performance pour l'exploitation des installations de chauffage, froid, ventilation, production ECS, traitement des eaux

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) — Competitive Grants Program. This opportunity will increase capacity of states and units of local government with existing crime laboratories to process DNA samples for entry into the Combined DNA Index System (CODIS). The purpose of the CEBR Competitive Program is to maximize the effective utilization of DNA technology to strengthen evidence-based criminal justice responses. The priorities of the CEBR Competitive Program are (1) to use DNA technology to increase the capacity and/or efficiency of publicly funded forensic DNA laboratories to conduct analysis of DNA samples for entry into CODIS and (2) implementing Rapid DNA in the booking station(s) in eligible jurisdictions. The program is designed to fairly and efficiently prioritize jurisdictions facing operational challenges by considering key performance measures reported by publicly funded forensic DNA laboratories. This program is for Competitive funding only. The BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) — Formula Grants Program for formula funding will post at a later date. Eligible agencies may apply for both Competitive and Formula CEBR Funding.

Sweden – Medical aids – Inhalationsutrustning och andningsmuskeltränare

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: Proposals are expected to contribute to all following points: The projects must fulfil the performance targets, at the cell and system level, corresponding to the specific targeted application, to be specified in the proposal. Appropriate KPI must be defined for the energy density (volumetric and gravimetric), Power density and C-rate, number of cycles and cost defined under operational conditions. Boost EU competitiveness in next-generation battery technologies for mobility applications. Develop pilot manufacturing capability for next generation lithium-based batteries. Strengthen the EU battery value chain, including new manufacturing equipment, automation, and scalable production processes. Advance the understanding of next-generation battery interfaces at an industrial scale, ensuring manufacturability, durability, and cost-effectiveness. In the case of aviation, the battery requirements should be compatible at minimum with EASA CS.23 (level 4), CS.27 and preferably with CS.25 categories. Scope: This topic will support the scaling-up of next generation (i.e., beyond generation 3) lithium-based batteries (e.g., semi and all-solid state, generation5) from cell…

Expected Outcome: This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certification of quantum components and systems. Expected outcomes include: Deployment of distributed quantum testing facilities accessible across Europe, including remote access and standardized test protocols. Provision of certification services aligned with future standardisation efforts, ensuring trust, quality, and interoperability of quantum technologies. Support for SMEs, start-ups, and research institutions in validating quantum components and sub-systems. Strengthening of Europe’s competitiveness by ensuring robust quality assurance mechanisms and accelerating the time-to-market of emerging quantum products. Scope: The proposal should implement the testing-related part of the action plan established under the Framework Partnership Agreement for Qu-Test. The action must include: Expansion and interconnection of open-access testing facilities in multiple Member States, covering a range of quantum technologies (e.g., processors, sensors, photonics, control systems). Development and deployment of…